Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Japan has committed to boosting testing and containment measures for the new coronavirus after confirming its first death, as well as new cases.

The country’s first casualty was a woman in her 80s in Kanagawa prefecture, Tokyo. The patient was confirmed to have contracted Covid-19 after death.

This fatality takes the number of deaths outside mainland China to three, including one each in the Philippines and Hong Kong.

On 13 February, the Japanese health ministry confirmed the country’s 30th case of coronavirus infection.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Japan Prime Minister Shinzo Abe was quoted by Reuters as saying: “We will stay in touch with local governments and expand our testing procedures and treatment of patients in order to prevent the spread.”

A task force is working to strengthen the country’s measures against the virus, including JPY10.3bn ($93.8m) in funding.

In a separate development, approximately 200 Japanese evacuees who returned from Wuhan on a second plane tested negative and left quarantine.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact